Project cooperationUpdated on 1 September 2025
Neo-adjuvant oncolytic immune activator
About
Background: Current immune checkpoint inhibitors (ICIs) fail in 80% of cancer patients, primarily due to "cold" tumor microenvironments that lack immune infiltration. ORCA-010 has demonstrated the unique ability to convert cold tumors to hot in 100% of treated patients through enhanced oncolytic viral activity and sustained immune activation.
Collaboration Opportunity: We seek strategic partnerships with pharmaceutical companies developing checkpoint inhibitors to explore combination therapy synergies. ORCA-010's proven ability to induce durable immune activation creates an ideal foundation for rational combination strategies with PD-1/PD-L1, CTLA-4, or next-generation checkpoint inhibitors.
Similar opportunities
Product
ORCA-010: Enhanced Oncolytic Immunotherapy Platform with 100% Immune Activation Success
Wenliang Dong
CEO at ORCA Therapeutics BV
Amsterdam, Netherlands
Service
Cell Therapy Development & Manufacturing
- Development
- Manufacturing
- Innovative therapies - Gene editing
- Innovative therapies - Stem cell therapy
- Innovative therapies - Immune cell therapy
- Innovative therapies - Somatic cell therapy
- Innovative therapies - Tissue engineered products
Sophia Kolbe
Business Developer at NecstGen
Leiden, Netherlands
Service
Viral Vector Development & Manufacturing
- Development
- Manufacturing
- Innovative therapies - Gene therapy
- Innovative therapies - Oncolytic viruses
Sophia Kolbe
Business Developer at NecstGen
Leiden, Netherlands